• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Increase in Diabetes and Obesity Numbers Driving Cardiovascular Drug Market Towards the $100 Billion Mark

Posted on: Tuesday, 5 December 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c46471) has announced the addition of Espicom Business Intelligence's new report: New Drug Futures: Cardiovascular Chapter to their offering.

Please note this chapter is taken from the "New Drug Futures" report.

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the cardiovascular sector. The report includes unique sales forecasts by major product.

Cardiovascular (CV) disease remains the number one killer in the US and Europe. In 2005, global sales of CV drugs were estimated to be worth around US$72.7 billion and accounted for around 12% of the world's total drug expenditure (US$600 billion). The majority of sales are derived from the US (around 52%) which has seen considerable growth (10.5% YoY) due to the uptake of new and more expensive medicines and more aggressive treatment of chronic conditions earlier during the course of the disease. Together Europe and Japan account for around 44% of sales with single digit growth.

By 2010, sales of CV drugs are expected to rise to around US$100 billion as the market continues to grow. The main drivers are an increase in diabetic and obese populations and the continued investment of pharmaceutical companies in the development of new classes of CV drugs to treat and prevent chronic CV conditions, as well as addressing areas of high unmet clinical need. The development of new imaging agents to improve CV diagnosis and treatment and improvement in surgical techniques associated with the treatment of CV diseases is critical to market expansion.

CV disease is the leading cause of death in the world, killing 17 million people each year. Many different aetiologies exist and key prevalence indicators include:

Stroke is the third leading cause of death in the major pharmaceutical markets. It is estimated that there were over 1.75 million stroke cases in the US (0.7 million) and Europe (1.05 million) each year. However only between 2%-8% of patients receive treatment on time.

Unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) are the leading cause of death in the Western world. Both are conditions of acute coronary syndrome (ACS), are recognised to be among the most frequent and important clinical manifestations of CAD.

Atrial fibrillation affects 2.5 million people in the US alone and is estimated to account for between 15 and 20% of all strokes and causes more than 37,000 deaths a year. Prevalence is expected to reach 5.6 million in the US by 2050. In the UK, AF affects 5% of the over 65 population and 10% of over 75s.

Answering key business questions

- Three drugs in this analysis have the potential to generate sales in excess of US$1 billion -- what are they?

- What advantage will Bayer's BAY 59-7939 have over low molecular weight heparins for the treatment of thrombosis/stroke? Does it have the potential to succeed where Exanta failed?

- AstraZeneca still has regulatory hurdles to overcome with its novel free-radical trapping neuroprotective agent Cerovive for stroke, but what are the potential sales rewards?

This chapter covers: Current Market Size

Addressable Patient Population

Current Treatments

Sales Drivers

Sales Breakers Future Treatments - Early Stage

Market Dynamics - Winners and Losers

Key launches to 2011

Competitor Ratio Analysis - Products

Competitor Ratio Analysis - Companies

Companies and Drugs Mentioned

- AGI 1067 (AtheroGenics/AstraZeneca)

- AZD7009 (IV) (AstraZeneca)

- BAY 59-7939 (Bayer/Johnson & Johnson)

- CERA (Roche/Chugai)

- Cerovive (AstraZeneca)

- Dronedarone (sanofi-aventis)

- Exjade (Novartis)

- Procoralan (Servier)

- Prasugrel (Eli Lilly/Sankyo)

- Ranexa (CV Therapeutics)

- Regadenoson (Astella/CV Therapeutics)

- Rasilez (Novartis)

- Revatio (Pfizer)

- Thelin (Encysive Pharmaceuticals)

- Torcetrapib/Lipitor (Pfizer)

For more information visit http://www.researchandmarkets.com/reports/c46471

Source: Espicom Business Intelligence

Source: Business Wire

More News in this Category